6
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2302 |
CNX-774
CNX 774 |
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
CNX-774 是一种选择性的、具有口服活性的、不可逆的 BTK 抑制剂 (IC50<1 nM)。它能够特异性靶向 Btk 的 Cys 481进行共价修饰。 | |||
T6008 |
CNX-2006
CNX 2006,CNX2006 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
CNX-2006 是一种新型的不可逆突变选择性 EGFR 抑制剂,对 EGFRT790M 的IC50值小于 20 nM。 | |||
T2256 |
CNX-1351
1-[4-[[2-(1H-吲唑-4-基)-4-(4-吗啉基)噻吩并[3,2-D]嘧啶-6-基]甲基]-1-哌嗪基]-6-甲基-5-庚烯-1,4-二酮 |
PI3K | PI3K/Akt/mTOR signaling |
CNX1351 是有效的、选择性的 PI3Kα 抑制剂,其 IC50=6.8 nM。 | |||
T10854 |
CNX-500
|
Others | Others |
CNX-500 is a probe consisting of a covalent Btk inhibitor chemically linked to biotin. CNX-500 has inhibitory activity against Btk (IC50: 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase EGFR and upstr | |||
T2369 |
Rociletinib
AVL-301,CNX-419,CO-1686 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Rociletinib (CNX-419) 是一种可口服的EGFR 抑制剂,能够抑制 EGFRL858R/T790M 和 EGFRWT 的活性,IC50值分别为 21.5 nM 和 303.3 nM。 | |||
T14993 |
Rociletinib hydrobromide
AVL-301 hydrobromide,CO-1686 (hydrobromide),CNX-419 hydrobromide |
Others | Others |
Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R/T790M and EGFR WT). |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04809 |
Calnexin Protein, Mouse, Recombinant (His)
calnexin,D11Ertd153e,AI988026,1110069N15Rik,Cnx |
Mouse | HEK293 Cells |
Calnexin Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 53.9 kDa and the accession number is P35564. | |||
TMPY-03112 |
Calnexin Protein, Human, Recombinant (hFc)
P90,calnexin,CNX,IP90 |
Human | HEK293 Cells |
Calnexin Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 79.4 kDa and the accession number is P27824. |